Nyxoah
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Belgium · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Rue Edouard Belin 12, Mont-Saint-Guibert...Phone Number
+3210222355Website
www.nyxoah.comRevenue
$25 MillionStock Symbol
NYXHIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Nyxoah
Nyxoah, located in Mont-Saint-Guibert, Belgium, is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA.Explore more
Nyxoah Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nyxoah your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Nyxoah launches new products
Funding: Get notified immidiatlly once Nyxoah has new funding data
Congratulate Masked Content for being promoted to Masked Content at Nyxoah
Nyxoah, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Nyxoah has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Nyxoah recently announced quarterly report
Click to see if Nyxoah had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Nyxoah is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Nyxoah is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nyxoah is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nyxoah.
Nyxoah financials insights
Gather financial insights about Nyxoah, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$11M
2016
Private Equity
$20M
2020
Private Equity
$27.2M
Stock Offering
$99.6M
2023
Share Placement
$15M
2024
Share Placement
$27M
2025
Stock/Share Issuance
$77M
2026
Private Equity
$95M
Nyxoah Tech Stack
A closer look at the technologies used by Nyxoah
Most Recent Scoops
Project
Nyxoah is currently conducting the ACCCESS trial in the United States to pursue Complete Concentric Collapse (CCC) label expansion for the Genio implant system, with early 2027 coding expected upon successful completion. This expansion is anticipated to significantly broaden the eligible patient pool, as CCC affects approximately 20% to 30% of hypoglossal nerve stimulation candidates and is currently contraindicated for unilateral stimulation solutions.
Clinical Operations
Hiring Plans
Nyxoah has announced plans to expand its US commercial team, growing from 25 sales representatives at the end of 2025 to 40 by adding 15 in Q1 2026, with all new hires trained and active as of April 1, 2026. The US team now totals over 60 personnel across sales, market access, and marketing, including 40 territory managers targeting high-volume accounts.
Hiring Plans, Training, Sales, Recruitment, HR Operations
Project
Nyxoah is in the process of completing data for its CCC (complete concentric collapse) Access study in the US, with a data readout expected in summer 2026, and plans to submit a supplement to the FDA to add a full CCC label indication, anticipated in 2027. Nyxoah already holds a CE mark for the CCC indication in Europe, with real-world outcomes demonstrated in Germany.
Medical Research, Clinical Operations
Project
Nyxoah has reported a serious adverse event rate of 8.7 percent in its Dream pivotal study, compared to approximately 20 percent for its primary competitor in their landmark pivotal study, representing less than half the serious adverse event rate.
Medical Research
Project
Medical Research, Clinical Operations
Nyxoah News & Media
Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026
Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day
Nyxoah (NASDAQ:NYXH) used its investor day presentation to outline early U.S. launch progress for its Genio hypoglossal nerve stimulation system, address reimbursement questions and describe its path toward profitability. Chief Executive Officer Olivier Taelman said there is “a lot of excitement inNyxoah Announces Preliminary Results for the Second Quarter of 2026
Nyxoah Announces Preliminary Results for the Second Quarter of 2026
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nyxoah
Sign Up For FreeTo access detailed company insights
Nyxoah, located in Mont-Saint-Guibert, Belgium, is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA.... Read More
